CADASIL
Clinical guidelines for managing hereditary stroke disorders, evaluating NOTCH3 gene mutations, temporal pole MRI parameters, and reviewing antiplatelet therapies and Migraine precautions.
Table of Contents
🧠 Standard of Care & Symptoms
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is the most common hereditary form of stroke and vascular dementia. It is caused by progressive damage to small blood vessels in the brain.
- Presentation: Key symptoms.
- *Migraine with Aura:* Often the first symptom, starting in a patient's 20s or 30s. Auras can be atypically prolonged or accompany motor weakness.
- *Recurrent Subcortical Strokes:* Symmetrical lacunar strokes occurring in young or middle-aged adults (ages 30-50), independent of classic vascular risk factors like Hypertension or smoking.
- *Cognitive Decline & Dementia:* Slowly progressive executive dysfunction, memory loss, and step-wise cognitive decline leading to vascular dementia.
- *Psychiatric Disturbances:* Severe mood disorders, primarily depression, apathy, or anxiety, affecting up to 30% of patients.
🧬 Diagnostics & NOTCH3 Pathophysiology
Diagnosis requires brain MRI, skin biopsy with electron microscopy, or confirmatory genetic testing of the NOTCH3 gene.
- Diagnostic Markers: Key criteria.
- Brain MRI (T2/FLAIR): Demonstrates extensive, symmetric white matter hyperintensities. A key diagnostic marker is the involvement of the **temporal poles** and **external capsules**, which is highly specific for CADASIL compared to chronic Hypertension.
- Genetic Testing: The gold standard. Confirms the presence of a pathogenic mutation in the **NOTCH3** gene.
- Skin Biopsy: Electron microscopy of skin blood vessels shows pathognomonic deposits of **granular osmiophilic material (GOM)** adjacent to vascular smooth muscle cells.
Pathophysiology of NOTCH3 Arteriopathy
The small vessel disease in CADASIL is driven by a specific genetic mutation:
- NOTCH3 Gene Mutation: The *NOTCH3* gene encodes a transmembrane receptor essential for **vascular smooth muscle cell (VSMC)** differentiation and survival. Pathogenic mutations involve a cysteine residue in the extracellular domain (EGFR repeats).
- Extracellular Accumulation: The mutated NOTCH3 receptor undergoes impaired clearance, leading to the accumulation of the **NOTCH3 extracellular domain (N3ECD)** on the surface of VSMCs in small-to-medium-sized penetrating cerebral arteries.
- VSMC Degeneration: This accumulation leads to the degeneration and loss of vascular smooth muscle cells. The vessel wall thickens, the lumen narrows, and autoregulation of blood flow is lost, precipitating subcortical ischemia.
💊 Stroke Prevention & Migraine Management
No disease-modifying therapies exist. Management is focused on reducing stroke risk, avoiding contraindicated Migraine medications, and supporting cognitive function.
Stroke Prophylaxis
- Antiplatelet Therapy: Oral **Aspirin** (75-325 mg daily) or **Clopidogrel** (75 mg daily) is used to reduce the risk of ischemic stroke. Anticoagulants (like Warfarin) are avoided unless specifically indicated (e.g. atrial fibrillation) due to an increased risk of microbleeds.
- Vascular Risk Factor Management: Aggressive control of blood pressure, cholesterol, and blood sugar, along with absolute smoking cessation, is mandatory to slow disease progression.
Migraine Contraindications
- Triptan and Ergot Avoidance: Vasoconstrictive medications (e.g. Sumatriptan, dihydroergotamine) are strictly contraindicated for treating migraines in CADASIL due to the high baseline risk of cerebral vasospasm and stroke. Non-vasoconstrictive therapies (like beta-blockers, CGRP antagonists, or Valproic Acid) are used for prevention.
🔬 Active Clinical Trials
Clinical trials are currently evaluating monoclonal antibodies to clear NOTCH3 aggregates, cerebrovascular hemodynamics optimizers, and antisense oligonucleotides.
Evaluating the safety and efficacy of a monoclonal antibody designed to bind and promote the clearance of NOTCH3 extracellular domain aggregates from cerebral blood vessels.
Key Inclusion: Age 18 to 65, genetically confirmed NOTCH3 mutation, and early signs of white matter changes on MRI.Investigating if low-dose Acetazolamide can improve cerebral blood flow autoregulation and reduce the frequency of transient ischemic attacks (TIAs) in symptomatic CADASIL patients.
Key Inclusion: Age ≥ 18, confirmed CADASIL, and at least one documented TIA or lacunar stroke in the preceding 6 months.A phase I study evaluating the safety of an intrathecally administered ASO designed to selectively knock down the expression of mutated NOTCH3 transcripts in the vascular wall.
Key Inclusion: Age 18 to 60, genetically confirmed NOTCH3 mutation, and progressive executive dysfunction.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with CADASIL, establish these clinical care pathways:
- Seek Genetic Counseling: Because CADASIL is inherited in an autosomal dominant pattern, each child of an affected individual has a 50% chance of inheriting the gene mutation.
- Review Migraine Medications: Work with a neurologist to immediately stop any triptan or ergot prescriptions.
- Control Vascular Risk Factors: Purchase a home blood pressure monitor and optimize your diet and exercise routines.
- Establish Cognitive Baselines: Complete neuropsychological testing to establish baseline executive function parameters.
❓ Patient FAQ
Q: How is CADASIL inherited?
A: CADASIL is an autosomal dominant condition. This means inheriting only one copy of the mutated NOTCH3 gene from one parent is sufficient to cause the disease. It does not skip generations.
Q: Can high blood pressure cause CADASIL?
A: No. CADASIL is caused entirely by genetic mutations in the NOTCH3 gene. However, having high blood pressure can significantly accelerate the blood vessel damage and increase the frequency of strokes, making strict blood pressure control a vital part of management.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.